US2017281585A1PendingUtilityA1

Methods for the treatment of sialorrhea

Assignee: NeuRx Pharmaceuticals LLCPriority: Nov 13, 2012Filed: Jun 20, 2017Published: Oct 5, 2017
Est. expiryNov 13, 2032(~6.3 yrs left)· nominal 20-yr term from priority
Inventors:Dinesh C. Patel
A61K 9/2054A61K 9/2018A61K 31/216A61K 9/7061A61K 9/2009A61K 9/0056
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides safe and effective methods for the treatment of sialorrhea (excessive drooling) by administering an effective amount of N-desethyloxybutynin, or an optical R- or S-isomer thereof or a pharmaceutically acceptable salt thereof.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of treating sialorrhea in a subject comprising:
 providing a therapeutically effective amount of a N-desethyloxybutynin compound; and   non-parenterally administering the therapeutically effective amount of the N-desethyloxybutynin compound to the subject.   
     
     
         2 . The method of  claim 1 , wherein the N-desethyloxybutynin comprises (R)-N-desethyloxybutynin or a pharmaceutically acceptable salt thereof or (S)-N-desethyloxybutynin or a pharmaceutically acceptable salt thereof, or a combination thereof. 
     
     
         3 . The method of  claim 1 , wherein the N-desethyloxybutynin is administered via oral, buccal, transdermal, inhalation, implantation, vaginal or rectal route of administration. 
     
     
         4 . The method of  claim 1 , wherein the N-desethyloxybutynin is orally administered. 
     
     
         5 . The method of  claim 4 , wherein the oral administration is administered either transmucosally through the oral cavity or enterally, or by a combination thereof. 
     
     
         6 . The method of  claim 1 , wherein the N-desethyloxybutynin is administered as an immediate release dosage form. 
     
     
         7 . The method of  claim 1 , wherein the N-desethyloxybutynin is administered as a controlled release dosage form. 
     
     
         8 . The method of  claim 1 , wherein the amount of N-desethyloxybutynin is from about 1 mg to about 100 mg. 
     
     
         9 . The method of  claim 8 , where in the amount is from about 2 mg to about 30 mg of N-desethyloxybutynin. 
     
     
         10 . The method of  claim 1 , wherein the N-desethyloxybutynin is administered as an oral tablet, capsule, or liquid.

Join the waitlist — get patent alerts

Track US2017281585A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.